Three distinct antiviral programs

Applying our expertise in immunology and virology, Kineta is conducting ground-breaking research into novel antiviral therapies and vaccine adjuvants for an array of emerging viruses. These immunotherapeutic drug development programs utilize leading edge science targeting the host response to infection via the innate immune system. It is a scientific approach with strong potential to circumvent the common problem of viral resistance.

  • Innate immune antivirals focused on a broad spectrum of respiratory and emerging viruses including: Dengue, Ebola, West Nile virus, Japanese Encephalitis, influenza, Respiratory Syncytial virus (RSV) and multiple corona viruses with potential efficacy against Middle Eastern Respiratory Syndrome (MERS).
  • A novel class of vaccine adjuvants to create more effective vaccines for pathogens such as pandemic influenza, Dengue virus and West Nile virus. Improvements to vaccine technology could vastly strengthen vaccination programs for underserved populations. Also, this technology is potentially applicable to the expanding realm of therapeutic vaccines in development for cancer.
  • LHF-535 is a direct-acting antiviral targeting Arenavirus infections including Lassa, Argentine and Bolivian hemorrhagic fevers. This novel small molecule inhibitor prevents viral entry into the cell and is being developed as an orally available drug for Lassa fever.